Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 16, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification from the Nasdaq Stock Market LLC (the "Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.As previously reported, on May 24, 2021,...
2022-05-16 9:05 AM EDT
Neovasc Announces First Quarter Financial Results and Provides Corporate Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 12, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the quarter ended March 31, 2022.Recent HighlightsAchieved Q1 revenue of approximately $611,000, an increase of 35% over the same period in 2021, delivering a record first quarter.Activated 6 sites, enrolled 21 patients, and, of those, randomized the first 4 patients, in the COSIRA II IDE trial for the Neovasc...
2022-05-12 4:05 PM EDT
Neovasc to Report First Quarter Financial Results on May 12, 2022
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 29, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on May 12, 2022.Interested parties may access the conference call by dialing (877) 407-9208 or (201)...
2022-04-29 9:05 AM EDT
Neovasc Comments on European Heart Journal Publication
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 28, 2022) - Neovasc, Inc. (NASDAQ: NVCN) TSX: NVCN) ("Neovasc" or the "Company") today announced that the European Heart Journal has published an article entitled, "Impact of Coronary Sinus Reducer on Absolute Blood Flow and Microvascular Resistance Case Report." The article, authored by Francesco Giannini, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes objective improvements in the amount of oxygenated blood...
2022-04-28 9:05 AM EDT
Neovasc Announces Effective Date of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation (reverse stock split) (the...
2022-04-27 4:05 PM EDT
Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX : NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen, Neovasc's Chief Executive Officer, will be presenting at 4:00 pm ET on Monday, May 2.The presentation can be accessed here. Additionally, a recording of the presentation will be...
2022-04-20 9:05 AM EDT
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
New York, New York--(Newsfile Corp. - April 13, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) "Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver, B.C. (the "Meeting").At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen to serve in...
2022-04-13 8:05 AM EDT
Neovasc Announces Consolidation and Extension of Convertible Debt
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that, pursuant to a Restated Securities Purchase Agreement with Strul Medical Group LLC ("SMG"), on a private placement basis (the "Private...
2022-03-24 9:05 AM EDT
Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 10, 2022) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021.HighlightsAchieved record revenue in Q4 of $759,000, an increase of 48% over the same period in 2020Achieved record revenue in 2021 of $2.55 million, an increase of 30% over the prior yearCommenced the COSIRA-II IDE clinical trial for Reducer in the United...
2022-03-10 4:05 PM EST
Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on March 10, 2022.Interested parties may access the conference call by dialing (877) 407-9208 or...
2022-02-24 9:00 AM EST
Neovasc Announces German Reimbursement Renewal and Commercial Progress
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022. Additionally, the Company announced the 500th patient has been treated in Germany.New examination and...
2022-02-08 9:05 AM EST
Independent Publication Reports Neovasc Reducer(TM) Demonstrates Cost Savings
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 4, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc ReducerTM ("Reducer").The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University of Sacro Cuore, Rome, included a budget impact analysis and a cost-utility analysis. The...
2022-02-04 9:05 AM EST
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 2, 2022) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the Southern District of New York. The consolidated amended complaint was dismissed in its entirety with...
2022-02-02 9:05 AM EST
Neovasc Announces Publication Supporting the Neovasc Reducer(TM) Device
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of an article entitled, "The Effectiveness of CS Reducer for the Treatment of Refractory Angina - a Meta-Analysis" in the Canadian Journal of Cardiology.The article's lead author and senior authors are Aviram Hochstadt, M.D., and Maayan Konigstein, M.D., Sourasky Medical Center and the Sackler School of Medicine,...
2022-01-20 9:05 AM EST
Neovasc Announces Case Series of First U.S. Reducer Implants Published in Peer-Reviewed Journal
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™ ("Reducer") under a compassionate use protocol in the United States. The patients were treated under the care of Ryan Gindi, M.D., and the procedures were performed by Gerald Koenig, M.D.,...
2022-01-18 9:05 AM EST
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 6, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022. A recorded presentation by Fred Colen, Neovasc's Chief Executive Officer, will be available on the conference website starting at 7:00 am EST on Monday, January 10. The recording will be...
2022-01-06 9:05 AM EST
Neovasc Announces First Patient Enrollment in COSIRA-II Trial
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 5, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced enrollment of the first patient in the COSIRA-II clinical trial. COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a pivotal trial that will study the Neovasc Reducer™ ("Reducer"), designed to reduce angina symptoms in patients with refractory angina. The results of this study will complement existing...
2022-01-05 9:05 AM EST
Neovasc to Participate in Sidoti December Virtual Microcap Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the Sidoti December Virtual Microcap Conference to be held December 8-9, 2021. Fred Colen, President and Chief Executive Officer, will give a presentation on Wednesday, December 8 at 3:15 pm EST. A link to the live webcast of the presentation will be available in the Investor...
2021-12-01 9:05 AM EST
Neovasc Reducer(TM) System Receives National Reimbursement in France
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 30, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Neovasc Reducer™ ("Reducer") system has been granted Prise en Charge Transitoire ("PECT") reimbursement in France by the national health authority, Haute Autorité de Santé ("HAS"). The decision will be officialized upon publication in the French Journal Officiel.The Reducer is the first therapy to be approved under...
2021-11-30 9:51 AM EST
Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has granted an additional 180 calendar day period within which to evidence compliance with the $1.00 bid price requirement following the expiration of the...
2021-11-24 1:24 PM EST